Articles with public access mandates - Marco MontilloLearn more
Not available anywhere: 5
Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study
P Baliakas, A Hadzidimitriou, LA Sutton, E Minga, A Agathangelidis, ...
The lancet haematology 1 (2), e74-e84, 2014
Mandates: US National Institutes of Health, Swedish Research Council, Government of Italy
Chronic lymphocytic leukemia with mutated IGHV4-34 receptors: shared and distinct immunogenetic features and clinical outcomes
A Xochelli, P Baliakas, I Kavakiotis, A Agathangelidis, LA Sutton, E Minga, ...
Clinical Cancer Research 23 (17), 5292-5301, 2017
Mandates: Swedish Research Council, European Commission, Government of Italy
MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL).
AP Kater, R Harrup, TJ Kipps, B Eichhorst, CJ Owen, S Assouline, ...
Hematological Oncology 41, 2023
Mandates: US National Institutes of Health, State of Califonia
How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia
M Deodato, AM Frustaci, P Sportoletti, L Laurenti, R Murru, A Visentin, ...
Leukemia & Lymphoma 63 (8), 1985-1988, 2022
Mandates: AIRC Foundation for Cancer Research in Italy
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial
A Tedeschi, AM Frustaci, A Condoluci, M Coscia, R Chiarle, PL Zinzani, ...
The Lancet Oncology, 2024
Mandates: European Commission
Available somewhere: 21
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
JC Byrd, JR Brown, S O'Brien, JC Barrientos, NE Kay, NM Reddy, ...
New England Journal of Medicine 371 (3), 213-223, 2014
Mandates: US National Institutes of Health
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
T Munir, JR Brown, S O'Brien, JC Barrientos, PM Barr, NM Reddy, ...
American journal of hematology 94 (12), 1353-1363, 2019
Mandates: US National Institutes of Health
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
JR Brown, P Hillmen, S O’brien, JC Barrientos, NM Reddy, SE Coutre, ...
Leukemia 32 (1), 83-91, 2018
Mandates: US National Institutes of Health
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3 …
AD Zelenetz, JC Barrientos, JR Brown, B Coiffier, J Delgado, M Egyed, ...
The Lancet Oncology 18 (3), 297-311, 2017
Mandates: US National Institutes of Health, American Heart Association
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
D Rossi, L Terzi-di-Bergamo, L De Paoli, M Cerri, G Ghilardi, A Chiarenza, ...
Blood, The Journal of the American Society of Hematology 126 (16), 1921-1924, 2015
Mandates: Cancer Research UK, National Institute for Health Research, UK, Fondazione …
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab
JC Byrd, P Hillmen, S O’Brien, JC Barrientos, NM Reddy, S Coutre, ...
Blood, The Journal of the American Society of Hematology 133 (19), 2031-2042, 2019
Mandates: US National Institutes of Health
Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study
AP Kater, JQ Wu, T Kipps, B Eichhorst, P Hillmen, J D’rozario, S Assouline, ...
Journal of Clinical Oncology 38 (34), 4042-4054, 2020
Mandates: US National Institutes of Health, State of Califonia
Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL
A Vardi, A Dagklis, L Scarfo, D Jelinek, D Newton, F Bennett, J Almeida, ...
Blood, The Journal of the American Society of Hematology 121 (22), 4521-4528, 2013
Mandates: Fondazione Cariplo
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL
A Agathangelidis, A Chatzidimitriou, K Gemenetzi, V Giudicelli, ...
Blood, The Journal of the American Society of Hematology 137 (10), 1365-1376, 2021
Mandates: Swiss National Science Foundation, US National Institutes of Health, German …
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
JF Seymour, TJ Kipps, BF Eichhorst, J D’Rozario, CJ Owen, S Assouline, ...
Blood, The Journal of the American Society of Hematology 140 (8), 839-850, 2022
Mandates: US National Institutes of Health, State of Califonia
Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations
P Baliakas, A Agathangelidis, A Hadzidimitriou, LA Sutton, E Minga, ...
Blood, The Journal of the American Society of Hematology 125 (5), 856-859, 2015
Mandates: US National Institutes of Health, Swedish Research Council, Government of Italy
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study
A Cuneo, G Follows, GM Rigolin, A Piciocchi, A Tedeschi, L Trentin, ...
haematologica 103 (7), 1209, 2018
Mandates: Blood Cancer UK, National Institute for Health Research, UK, Government of Italy
Prognostic factors for complete response to ibrutinib in patients with chronic lymphocytic leukemia: a pooled analysis of 2 clinical trials
SM O’Brien, S Jaglowski, JC Byrd, R Bannerji, KA Blum, CP Fox, ...
JAMA oncology 4 (5), 712-716, 2018
Mandates: US National Institutes of Health
Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
A Tedeschi, AM Frustaci, FR Mauro, A Chiarenza, M Coscia, S Ciolli, ...
Blood Advances 5 (24), 5490-5500, 2021
Mandates: AIRC Foundation for Cancer Research in Italy
No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets# 1 and# 2 treated with chemo (immuno) therapy
P Baliakas, M Mattsson, A Hadzidimitriou, E Minga, A Agathangelidis, ...
Haematologica 103 (4), e158, 2018
Mandates: Swedish Research Council, European Commission, Government of Italy
Publication and funding information is determined automatically by a computer program